文献速递生殖医学产科

黄体期刺激来源的整倍体囊胚与卵泡期刺激来源者临床、产科及围产结局相同:多中心研究

The euploid blastocysts obtained after luteal phase stimulation show the same clinical, obstetric and perinatal outcomes as follicular phase stimulation-derived ones: a multicenter study.
PubMed 文献 · Hum Reprod · 2020-01-01

多中心研究比较卵泡期刺激(FPS)与黄体期刺激(LPS)来源的整倍体囊胚在冻融单囊胚移植后的生殖结局。共纳入389例首次移植优质整倍体囊胚,LPS组与FPS组的活产率分别为49%与44%(P=0.3),产科及围产结局无显著差异。

要点

  • LPS与FPS来源整倍体囊胚的活产率无显著差异(49% vs 44%,P=0.3)。
  • 两组妊娠期问题、围产期问题、孕周及出生体重等指标均相似。
  • DuoStim方案中LPS来源囊胚在临床、产科及围产方面是安全的。

核心结论

  • LPS来源的整倍体囊胚在冻融单囊胚移植后的临床、产科及围产结局与FPS来源者无差异。

研究设计与样本

  • 多中心研究,2015年10月至2019年3月,纳入所有DuoStim后冻融单整倍体囊胚移植,仅首次移植优质囊胚(≥BB)。
  • 共389例患者接受冻融单囊胚移植(FPS组182例,LPS组207例),其中126例双组均有可用囊胚者采用随机数盲选移植胚胎。

主要发现

  • FPS组与LPS组阳性妊娠率分别为57%与62%,生化妊娠丢失率10%与8%,流产率15%与14%。
  • 活产率FPS组44%(80/182,95%CI 37-51%),LPS组49%(102/207,95%CI 42-56%),P=0.3。
  • 调整囊胚发育天数与质量后,LPS vs FPS活产OR=1.3(95%CI 0.8-2.0,P=0.2)。
  • 双组均有整倍体囊胚者中,活产率FPS组53%(37/70,95%CI 41-65%),LPS组48%(27/56,95%CI 35-62%),P=0.7。
  • 妊娠期问题FPS组7.5%、LPS组10%;围产期问题FPS组5%、LPS组0%;两组早产率均为5%。

关键数值与推荐

  • 主要结局为每冻融单整倍体囊胚移植的活产率,需366例首次移植以达到80%把握度排除15%差异。
  • 囊胚质量按Gardner和Schoolcraft分类,仅纳入≥BB者。
  • FPS与LPS采用相同卵巢刺激方案(GnRH拮抗剂固定剂量rec-FSH+rec-LH,GnRH激动剂扳机)及相同培养和实验室流程。

临床怎么用

  • DuoStim方案中LPS来源的整倍体囊胚可安全用于移植,临床、产科及围产结局与FPS来源者相当。
  • 对需在最短时间内获得整倍体囊胚移植的患者(如癌症、高龄、卵巢储备减退或低反应者),LPS后行DuoStim是可行且高效的选择。

局限性

  • LPS来源囊胚均在DuoStim方案中FPS之后获得,需进一步研究仅LPS、晚FPS及随机起始方案。
  • 研究把握度仅针对每移植活产率,产科及围产结局应视为观察性。
  • 研究为前瞻性但未注册。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: Are the reproductive outcomes (clinical, obstetric and perinatal) different between follicular phase stimulation (FPS)- and luteal phase stimulation (LPS)-derived euploid blastocysts? SUMMARY ANSWER: No difference was observed between FPS- and LPS-derived euploid blastocysts after vitrified-warmed single embryo transfer (SET). WHAT IS KNOWN ALREADY: Technical improvements in IVF allow the implementation non-conventional controlled ovarian stimulation (COS) protocols for oncologic and poor prognosis patients. One of these protocols begins LPS 5 days after FPS is ended (DuoStim). Although, several studies have reported similar embryological outcomes (e.g. fertilization, blastulation, euploidy) between FPS- and LPS-derived cohort of oocytes, information on the reproductive (clinical, obstetric and perinatal) outcomes of LPS-derived blastocysts is limited to small and retrospective studies. STUDY DESIGN, SIZE, DURATION: Multicenter study conducted between October 2015 and March 2019 including all vitrified-warmed euploid single blastocyst transfers after DuoStim. Only first transfers of good quality blastocysts (≥BB according to Gardner and Schoolcraft's classification) were included. If euploid blastocysts obtained after both FPS and LPS were available the embryo to transfer was chosen blindly. The primary outcome was the live birth rate (LBR) per vitrified-warmed single euploid blastocyst transfer in the two groups. To achieve 80% power (α = 0.05) to rule-out a 15% difference in the LBR, a total of 366 first transfers were required. Every other clinical, as well as obstetric and perinatal outcomes, were recorded. PARTICIPANTS/MATERIALS, SETTING, METHODS: Throughout the study period, 827 patients concluded a DuoStim cycle and among them, 339 did not identify any transferable blastocyst, 145 had an euploid blastocyst after FPS, 186 after LPS and 157 after both FPS and LPS. Fifty transfers of poor quality euploid blastocysts were excluded and 49 patients did not undergo an embryo transfer during the study period. Thus, 389 patients had a vitrified-warmed SET of a good quality euploid blastocyst (182 after FPS and 207 after LPS). For 126 cases (32%) where both FPS- and LPS-derived good quality blastocysts were available, the embryo transferred was chosen blindly with a 'True Random Number Generator' function where '0' stood for FPS-derived euploid blastocysts and '1' for LPS-derived ones (n = 70 and 56, respectively) on the website random.org. All embryos were obtained with the same ovarian stimulation protocol in FPS and LPS (GnRH antagonist protocol with fixed dose of rec-FSH plus rec-LH and GnRH-agonist trigger), culture conditions (continuous culture in a humidified atmosphere with 37°C, 6% CO2 and 5% O2) and laboratory protocols (ICSI, trophectoderm biopsy in Day 5-7 without assisted hatching in Day 3, vitrification and comprehensive chromosome testing). The women whose embryos were included had similar age (FPS: 38.5 ± 3.1 and LPS: 38.5 ± 3.2 years), prevalence of male factor, antral follicle count, basal hormonal characteristics, main cause of infertility and previous reproductive history (i.e. previous live births, miscarriages and implantation failures) whether the embryo came from FPS or LPS. All transfers were conducted after warming in an artificial cycle. The blastocysts transferred after FPS and LPS were similar in terms of day of full-development and morphological quality. MAIN RESULTS AND THE ROLE OF CHANCE: The positive pregnancy test rates for FPS- and LPS-derived euploid blastocysts were 57% and 62%, biochemical pregnancy loss rates were 10% and 8%, miscarriage rates were 15% and 14% and LBRs were 44% (n = 80/182, 95% CI 37-51%) and 49% (n = 102/207, 95% CI 42-56%; P = 0.3), respectively. The overall odds ratio for live birth (LPS vs FPS (reference)) adjusted for day of blastocyst development and quality, was 1.3, 95% CI 0.8-2.0, P = 0.2. Among patients with euploid blastocysts obtained following both FPS and LPS, the LBRs were also similar (53% (n = 37/70, 95% CI 41-65%) and 48% (n = 27/56, 95% CI 35-62%) respectively; P = 0.7). Gestational issues were experienced by 7.5% of pregnant women after FPS- and 10% of women following LPS-derived euploid single blastocyst transfer. Perinatal issues were reported in 5% and 0% of the FPS- and LPS-derived newborns, respectively. The gestational weeks and birthweight were similar in the two groups. A 5% pre-term delivery rate was reported in both groups. A low birthweight was registered in 2.5% and 5% of the newborns, while 4% and 7% showed high birthweight, in FPS- and LPS-derived euploid blastocyst, respectively. Encompassing the 81 FPS-derived newborns, a total of 9% were small and 11% large for gestational age. Among the 102 LPS-derived newborns, 8% were small and 6% large for gestational age. No significant difference was reported for all these comparisons. LIMITATIONS, REASONS FOR CAUTION: The LPS-derived blastocysts were all obtained after FPS in a DuoStim protocol. Therefore, studies are required with LPS-only, late-FPS and random start approaches. The study is powered to assess differences in the LBR per embryo transfer, therefore obstetric and perinatal outcomes should be considered observational. Although prospective, the study was not registered. WIDER IMPLICATIONS OF THE FINDINGS: This study represents a further backing of the safety of non-conventional COS protocols. Therefore, LPS after FPS (DuoStim protocol) is confirmed a feasible and efficient approach also from clinical, obstetric and perinatal perspectives, targeted at patients who need to reach the transfer of an euploid blastocyst in the shortest timeframe possible due to reasons such as cancer, advanced maternal age and/or reduced ovarian reserve and poor ovarian response. STUDY FUNDING/COMPETING INTEREST(S): None. TRIAL REGISTRATION NUMBER: N/A.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Vaiarelli A, Cimadomo D, Alviggi E, et al. The euploid blastocysts obtained after luteal phase stimulation show the same clinical, obstetric and perinatal outcomes as follicular phase stimulation-derived ones: a multicenter study. Hum Reprod. 2020. PMID: 32951051. doi:10.1093/humrep/deaa203

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。